Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | BMC Immunology

Fig. 5

From: Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren’s syndrome

Fig. 5

Artemisinin reduced Th17 cells and expanded Tregs in NOD/Ltj mice. A and B Tregs and IL-17 in lymphocytes measured by flow cytometry. C The proportion of Tregs. D The proportion of IL-17. a: normal group, b: NOD/Ltj model group, c: artemisinin group, d: HCQ group (*P < 0.05 compared with the normal group; #P < 0.05 compared with the model group)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us